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1. Introduction 
Quality system is defined as arrangements, procedures, processes and resources; and the 
systematic actions necessary to ensure that a manufactured product will meet given 
specifications. On the other hand, quality control is defined as measures taken, including 
sampling and testing, to ensure that raw materials, intermediates, packaging materials and 
finished goods conform to given specifications. Quality specification refers to a written 
procedure and requirements that a raw material, intermediate or finished good must meet 
for approval. On the other hand, standard operating procedure (SOP) refers a written 
procedure, giving step-by-step directions on how a particular operation is to be carried out. 
Quality manual means, a document that describes the various elements of the system used 
in assuring the quality of results or products generated by a laboratory or factory. The term 
quality assurance refers to the totality of all the arrangements made with the objective of 
ensuring that products are of the quality required for their intended use. Good 
manufacturing practice (GMP), on the other hand, is that aspect of quality control that deals 
directly with manufacturing and testing of raw materials, intermediates and finished goods 
to ensure a product of consistent quality. Essentially, GMP involves two types of control - 
analytical and inspection, and both require: i) clear instructions for every manufacturing 
process; ii) a means of controlling and recording every manufacturing process; iii) a means 
of ensuring that the complete history of a batch can be traced; iv) a mechanism for recalling 
any batch of product from circulation; v) a system for attending to complaints on quality of 
product or service; and vii) a programme for training operators to carry out and to 
document procedures. The foregoing definitions and description of GMP conform to those 
of WHO (2000). It is also clear from the foregoing that GMPs are not prescriptive 
instructions on how a manufacturer can produce, but are rather a series of principles that 
must be observed for quality products, services or results to emerge.  Invariably, GMPs are 
approved and enforced by an appropriate National Agency, but the onus of preparing and 
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executing GMPs rests with the manufacturer. In Nigeria (population ~ 150 million), GMPs 
are enforced by NAFDAC – established by decree in 1992/93.  
The tests carried out for this study were according to official procedures - mostly BP (2004) 
and WHO (1998). The results are discussed within the context of requirements for herbal 
drug regulation as per WHO, EMEA and NAFDAC. It is noted that herbal drug regulation 
in Nigeria (Table 1) as compared that in Europe (Table 2) is paradoxically hampered not by 
the rigor and “stringency” of rules, but by the fact that the rules are only merely 
cumbersome, being neither adequate nor enforceable (Table 3), unlike those of EMEA. 
 
S/No. Regulatory aspect Requirement 
1 
Legal status of applicant, who may be: 
Manufacturer. 
Marketer. 
Distributor.  
The applicant must be certified by the 
Corporate Affairs Commission as a 
registered business in Nigeria.  
A marketer or distributor must show 
evidence of Power of Attorney issued by 
the manufacturer. 
2 
Analytical status of the product for 
registration.  
The product must : 
Have a certificate of analysis. 
Be accompanied by a dossier with 
information on: 
Ingredients. 
 Method of analysis. 
Stability. 
Dosage. 
Safety, among others.  
3 Pre-registration inspection of premises.  
Manufacturing, storage and distribution 
premises must be GXP compliant.  
Marketers must provide convincing 
evidence of GDP and GSP.  
4 Post marketing surveillance plan/ report  
Applicant may be required to provide a 
plan for reporting on: 
The use of the product. 
Any adverse reactions.  
The above information were drawn from NAFDAC’s leaflets and website: www.nafdacnigeria.org  
Table 1. NAFDAC requirements for registering herbal medicines. 
Essentially, the NAFDAC rules seem perhaps affected, or rather made cumbersome without 
being truly rigorous or “stringent” as actually claimed in the Agency’s website. It is further 
noted that, like in China, where the head of the drug regulatory agency was sentenced to 
death for corruption (Gross and Minot, 2007), drastic actions, including the wholesale 
reorganization of NAFDAC management, had to take place in 2000 to straighten things out. 
The high frequency of confiscation and public destruction of counterfeit products by 
NAFDAC strongly testifies to the inadequacy of the rules and policies guiding drug 
regulation in Nigeria. Unfortunately, this worrisome state of affairs is equally true of many 
countries, as stated in the case of china. There is thus, the need for drug regulatory agencies 
in these countries to brace up. The aim of this article therefore, is to further an earlier 
advocacy (Ameh et al., 2010a) that includes alerting and encouraging Drug Regulatory 
Agencies, Health Ministries, and Parliamentary Health Committees, especially those in 
developing countries, to enact laws and evolve policies that will better regulate the 
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S/No. Regulatory aspect Requirement 
1 
Product 
information: 
Summary of product 
characteristics 
Name of the product.  
Strength.  
Dosage form.  
Quantity of active ingredient (Example: 25 mg P. guineense).  
List of excipients (Example: P. guineense, E. caryophyllata etc., etc).  
Shelf life.  
Posology and method of administration.  
Indications.  
Contraindications/ special warnings.  
Precautions for use.   
These data are used as the basis for inserts, packaging, or 
advertisement. Inserts must pass “readability testing.” 
2 
Quality control 
data:  
Refer to GMP 
requirements for 
production.  
Production must be in a GMP compliant facility 
Drug must be produced with validated/ reproducible formula 
method. 
There must be a finished product specification.   
The product must be manufactured at least on pilot scale and 
three batches used for stability studies. 
Stability studies should be carried out on the product packaged in 
the container proposed for marketing. 
A summary of the stability studies undertaken must be provided. 
From stability data shelf life/ storage precautions should be 
proposed. 
A quality dossier must be provided for raw and finished materials 
The product must be produced from herbs that have been 
cultivated and harvested in accordance with GACP.  10.  
The starting material must be evaluated for risk of any 
environmental contamination.  
3 
Safety data 
requirements: 
Refers to safety 
pharmacology, 
including animal 
and human studies 
Published animal or human studies.  
Review of any potential interactions with other drugs, side effects, 
and any proposed contraindications/ precautions in the product 
information.  
Recognized monographs on the material or product with 
information on safety.  
Any information concerning special groups such as children, the 
elderly or pregnant women.  
It is interesting to note that in the US, where herbal medicines are 
regulated as dietary supplements, manufacturers are not required 
to prove safety or efficacy, but the FDA can withdraw a product 
from sale if it proves harmful.  
4 
Traditional use 
evidence: Refers to 
history and 
prevalence.  
There is no requirement to prove efficacy. 
Instead data must provide reference that the product has been in 
use as medicine for 30 years or more. 
Of 30 or more years, the last 15 must be in Europe.  
The data must be presented in a special format, called: Common 
Technical Document Format. 
The Table was drawn based on data gathered from references including (DSHEA 1994; Goldman, 2001; 
De Smet, 2005; Ann Godsell Regulatory, 2008). 
Table 2. EMEA requirements for registering herbal medicines. 
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S/No. Extra requirement Remark  
1 Five (5) copies of the product dossier. Probably unreasonable 
2 
Three (3) packs of the products samples. 
 
Probably reasonable 
3 
Notarized original copy of the duly executed Power of 
Attorney from the product manufacturer. 
Clearly unreasonable for all 
categories of applicants 
4 
Certificate of Manufacture issued by the competent 
health or regulatory authority in country of origin and 
authenticated by the Nigerian Mission in that country. 
Where there is no Nigerian mission, The British High 
Commission or an ECOWAS country Mission will 
authenticate. 
Probably unreasonable for all 
categories of applicants 
5 
If contract-manufactured, Contract Manufacturing 
Agreement, properly executed and notarized by a 
Notary Public in the country of manufacture. 
Clearly unreasonable for all 
categories of applicants 
6 
Current World Health Organization Good 
Manufacturing Practice Certificate for the 
manufacturer, authenticated by the Nigerian Mission. 
Clearly unreasonable for all 
categories of applicants 
7 
Certificate of Pharmaceutical Products (COOP) duly 
issued and authenticated. 
Clearly unreasonable for all 
categories of applicants 
8 
Current Superintendent Pharmacists license to 
practice issued by the Pharmacists Council of Nigeria 
(PCN). 
Only probably reasonable  
9 Premises Registration License from PCN Only probably reasonable 
10 
Certificate of Registration of brand name with 
trademark registry in the Ministry of Commerce here 
in Nigeria; Letter of invitation from manufacturer to 
inspect factory abroad, stating full name and location 
of plant.
Probably unreasonable for all 
categories of applicants 
11 
The applicable fee payable only if documents are 
confirmed to be satisfactory. 
Likely to be abused if the 
amount is high. The fee should 
be a token amount paid by all 
applicants
12 
Nutraceuticals, medical devices and other regulated 
drug products have similar requirements, with minor 
variations. Specific details can be obtained from 
NAFDAC. 
A sketch of the minor variations 
should be provided in print no 
matter how brief. Any 
information provided by 
NAFDAC should be printable 
for sake of transparency. 
The information on NAFDAC were drawn from leaflets and NAFDAC’s website (2010): 
www.nafdacnigeria.org/ The remarks are informed by current affairs and public perception  
of NAFDAC’s role and activities including the wholesale reorganization of its Management  
in 2000. 
Table 3. NAFDAC’s extra requirements for registering herbal medicines. 
production, distribution and use of herbal drugs. This is in view of the ever increasing use of 
herbs notably after the Alma-Ata Declaration (Ameh et al, 2010b) which paved the way for 
the stupendous growth of herbal drug use worldwide, particularly in North America where 
that growth had been stymied by the Flexner Report of 1910. That Report, which coincided 
with Paul Ehrlich’s introduction of Salvarsan and the term “chemotherapy” in 1909, had 
favoured chemical medicine over herbal (Pelletier, 2006). Furthermore, apart from the said 
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growing use in the West, it is held that some 80 % of the populace in many developing 
countries still relies predominantly on herbs and other alternative remedies (WHO, 2008). 
Indeed, in some parts of Africa, for example, Ethiopia, a dependence of up to 90% has been 
claimed (BBC, 2006). 
2. Experimental 
The study applied official procedures – mainly WHO (1998) and BP (2004) to: evaluate the 
quality parameters of the raw materials and their extracts; and the changes in these 
parameters during dark, dry storage in capped glass bottles under tropical room 
temperature and humidity (RTH) as obtain in a typical Nigerian Traditional Apothecary 
(NTA). The parameters evaluated were: appearance, loss on drying, ash values, 
extractability, solubility, pH, TLC features, light absorption and foaming index. Basic 
morphological studies were carried out as per WHO (1998). Appropriate phytochemical 
tests were also conducted by official methods as described elsewhere (Ameh et al., 2010c; 
2010d).  
2.1 Treatment and sampling of material 
The aerial parts of Mitracarpus scaber obtained during the months of October and November 
from the botanical garden of the National Institute for Pharmaceutical Research and 
Development (NIPRD) were air-dried in a well-ventilated shade, designed for drying 
medicinal plant materials. The materials were subsequently comminuted to coarse powder 
with a grinding machine. The procedure for sampling was as per WHO (1998) as had been 
described in detail earlier (Ameh et al., 2010c). Three (3) original samples from each batch or 
container were combined into a pooled sample and subsequently used to prepare the 
average sample. The average sample was prepared by “quartering” the pooled sample as 
follows: each pooled sample was mixed thoroughly, and constituted into a square-shaped 
heap. The heap was then divided diagonally into 4 equal parts. Any 2 diagonally opposite 
parts were taken and mixed carefully. This step was repeated 2 to 4 times to obtain the 
required quantity of sample. Any material remaining was returned to the batch. The final 
samples were obtained from an average sample by quartering, as described above. This 
means that an average sample gave rise to 4 final samples. Each final sample was divided 
into 2 portions. One portion was retained as reference material, while the other was tested in 
duplicate or triplicate. The samples for stability study were stored at room temperature and 
humidity (RTH) in capped glass bottles and placed in a shelf protected from light. 
2.2 Macroscopic examination and phytochemical tests on the fresh and air-dried 
materials 
The procedures adopted were as per WHO (1998). Shape and size were determined with the 
aid of a ruler and a pair of calipers. Diffuse day light was used on the untreated sample to 
determine its colour. The texture and surface/ fracture characteristics of the untreated 
sample were examined, where necessary, with x10 magnification hand lens to reveal the 
characteristics of cut surfaces. The material was felt by touch, to determine if it was soft or 
hard. Or was bent and ruptured, to obtain information on brittleness and appearance of 
fracture planes – whether it was fibrous, smooth, rough or granular. Odour was determined 
by placing a pinch in a 50-ml beaker, and then slowly and repeatedly the air above the 
material was inhaled. If no distinct odour was perceived, the material was crushed between 
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the thumb and index finger, and inhaled as above. The strength of the odour was 
determined as: odourless, weak, distinct, or strong. The sensation of the odour was 
determined as: aromatic, fruity, rancid, etc. etc. When possible, the odour was compared 
with that of a defined substance, such as menthol, sulphur dioxide, eugenol, etc. etc. Taste: 
In tasting the material, as recommended by our experience with the material, the following 
procedure was applied: a pinch of the material was mixed with water and savored, or 
chewed without swallowing, to determine the strength and the sensation of the taste. The 
strength is recorded as: tasteless, weak, distinct, or strong; and the sensation, as: sweet, sour, 
saline, or bitter. Phytochemical tests for tannins, saponins, terpenoids, anthraquinones and 
alkaloids were carried out on samples by procedures as described in detail elsewhere (Ameh 
et al., 2010c, d).  
2.3 Loss on drying 
This was carried out using a minimum of 0.5 – 1.0 g of material. Drying was effected in a 
Lindberg/Blue M gravity-convention oven maintained at 105-110 0C, for 3 h, after which the 
sample was allowed to cool to room temperature in a desiccator, and subsequently weighed. 
The time interval from the oven to point of weighing was usually about 30 minutes. The 
results are expressed as a range or as mean ± standard deviation. 
2.4 Evaluation of extractive matter 
About 4 g of accurately weighed coarsely powdered, air-dried sample was transferred into a 
glass-stoppered, 250-ml reflux conical flask, followed by the addition of 100 ml of solvent. 
The flask was weighed along with its contents, and recorded as W1. The flask was well 
shaken, and allowed to stand for 1 h. Subsequently a reflux condenser was attached to the 
flask, and gently brought to boiling and maintained thereat boiled 20 – 60 minutes 
depending upon the solvent. The mixture was subsequently cooled and weighed again. The 
weight was recorded as W2, and then readjusted to W1 with the solvent. The flask was 
shaken well once again and its contents rapidly filtered through a dry filter paper. By means 
a pipette, 25 ml of the filtrate was transferred to a previously dried and tarred glass dish and 
then gently evaporated to dryness on a hot plate. Subsequently, the dish was dried at 105 ºC 
for 1-6 hours, cooled in a desiccator for 30 min, and weighed. The extractable matter was 
calculated as %w/w of the air-dried sample. 
2.5 Determination of solubility of material in a given solvent – Methods I and II 
The solubility of a material was determined at room temperature ~ 25ºC and expressed in 
terms of “parts’, representing the number of milliliter of solvent, in which 1 g of the material 
is soluble. Vials of appropriate sizes: ~4-ml, ~ 12-ml and ~20-ml capacities were used. The 
mixtures were thoroughly shaken for at least 30 min before inspection for un-dissolved 
solute. In methods I, each vial received 100 mg of sample and the volume of solvent 
indicated. In method II, a vial received 100 mg and increasing volumes of solvent. The 
methods give the same results.  
2.6 Light absorption and thin layer chromatography (TLC) 
UV-VIS Spectrophotometer (Jenway or Shimadzu) and quartz 1-cm cells were used for the 
study. Solutions of herb and extract were made by thoroughly mixing 1 part of the solute 
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and with 100 parts of solvent methanol: water 80:20, v/v filtering, and diluting the filtrates 
by 150x with the same solvent. Absorbencies were measured at ǌ227 nm, using the solvent 
as the blank. Florescent, precoated plates were used for normal phase TLC, utilizing silica 
K6, and hexane: ethylacetate as mobile phase. Solutions of analytes were prepared and 
applied as follows: To 1 mg of the analyte, 2 drops of ethanol were added and mixed well 
(~1 %w/v solution). The plates used were 5 cm wide x 20 cm long. With a ruler and a pencil, 
a distance of 5 mm was measured from the bottom of the plate, and a line of origin was 
lightly drawn across the plate, without disturbing the adsorbent. The analyte was applied to 
the origin as a 1 Ǎl droplet. The spot was allowed to dry. Subsequently, the plate was 
developed in a developing tank saturated with the vapour of the solvent system to be used 
as mobile phase. The level of the solvent in the tank was adjusted to a level 2 to 3 mm below 
the line of origin on the plate. The plate was considered developed when the solvent front 
reached a predetermined line, not less than 5 mm below the top of the plate. The air-dried 
plate was visualized using a viewing cabinet (Cammag) and a UV-lamp (Cammag – 
equipped to emit light at 254 or 366 nm). The resulting chromatogram was photographed 
and subsequently drawn to scale. 
2.7 Determinations of pH of preparations – herb and the dry extract 
Determination of pH values was with a Jenway pH Meter. Standard pH solutions: 4, 7 and 
10; and freshly distilled water were used for the study.  
2.8 Determination of foaming indices of preparations – herb and the dry extract 
Decoctions of plant materials foam due to the presence of saponins. This ability is measured 
as foaming index, and is an important quality control parameter. The requirements for the 
test include: conical flasks (500-ml); volumetric flasks (100-ml); test tubes (16cm x 16mm); 
ruler; and stop-clock. The procedure was as follows: Exactly 1.0 g of powdered material was 
accurately transferred into a 500-ml conical flask containing 100 ml of boiling water, and 
maintained at moderate boiling for 30 minutes. The mixture was then cooled and filtered 
into a 100-ml volumetric flask.  The volume was made up to 100 ml with water. Successive 
portions of 1 ml, 2 ml, 3 ml etc up to 10 ml of the filtrate was poured into ten stoppered 
tubes having the following dimensions: height, 16 cm; diameter, 16 mm. Subsequently, the 
volume of each tube was adjusted to 10 ml with water, stoppered and shaken in lengthwise 
motion for 15 seconds, at 2 shakes per second. The tubes were allowed to stand for 15 
minutes, and the height of the foam in each tube was measured. The results were assessed 
as follows: 
Foaming index is ≤ 100, if the height of foam in all the tubes is less than 1 cm. 
If a height of 1 cm is obtained in any tube, the volume [V] of the decoction in that tube, is 
used to determine the foaming index, as = 1000/V.  
But if the tube above is the first or the second in the series, prepare an intermediate dilution 
to obtain a more precise result. 
If the height of the foam is > 1 cm in every tube, the foaming index is over 1000.  
To obtain a more precise result, repeat the determination using a new series of dilutions of 
the decoction. Note the tube in which the height of foam is 1 cm, and the volume [V] of 
the decoction therein, and calculate the foaming index, as = 1000/V. Results are 
expressed as expressed as a quantity [Q] per ml or as [Q]ml-1. 
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3. Results 
3.1 Results of botanical examination / phytochemical tests on the herb and extract 
The key botanical and phytochemical characteristics of Mitracarpus scaber Zucc (Family: 
Rubiaceae) with Voucher specimen number: NIPRD/H/4208, preserved in the Institute’s 
Herbarium are indicated in Table 4. The plant grows erect, up to 55 cm high, usually 
branched; the leaves are lanceolate, 2-4 cm long, with the upper surface bearing minute 
hairs. The plant manifests dense clusters of inflorescence, 6-14 mm across, with minute 
white flowers. The fruits are dehiscent capsules, about 0.5-1 mm long. Both the fresh plant 
and air-dried weed are practically odourless but possess a slight warm taste. Tannins, 
saponins and anthraquinones were detected in the weed. The extract also contained tannins 
and anthraquinones but not saponins. Tests for alkaloids were negative for the weed and 
extract.  
 
Characteristic  Live Sample Air-dried Sample 
General 
appearance 
 
M. scaber is an annual, with erect 
stems, up to 55 cm high, and 
often branched. The leaves are 
lanceolate, 3-5 cm long, with the 
upper surface scabrous. The 
inflorescence consists of clusters 
of small white flowers. The fruits 
are dehiscent capsules, up to 1 
mm long. The plant is of the 
Family, Rubiaceae, reproduces 
by seeds, and is found in the 
tropics. 
 
The air-dried sample consists of 
brownish green twigs and other 
parts that can readily be ground 
in a mortar or comminuting 
machine. The air-drying process 
takes about a week during the 
months of October to December, 
at NIPRD Herbarium, Abuja. The 
extracts obtained with various 
solvents yield a black, odorless 
and sticky mass. 
Odor Odourless Odourless 
Taste Very slightly warm Slightly warm 
Phytochemicals 
Tannins, saponins and 
anthraquinones were detected. 
The tests for alkaloids were 
negative. 
Tannins and anthraquinones 
were detected. The tests for 
alkaloids and saponins were 
negative. 
The samples described above were obtained from the NIPRD Botanical Gardens at Idu Industrial Area, 
Idu, Abuja, Federal Capital Territory, Nigeria.  
Table 4. Some key characteristics of Mitracarpus scaber and its aerial parts. 
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3.2 Results of physicochemical tests on the herb and extract of Mitracarpus scaber 
Typical results of loss on drying (LOD as %w/w was 10.29 ± 1.81 for the herb; and 15.86 ± 
0.72 for the extract) and total ash (TA as %w/w was 12.44 ± 2.95 for the herb; and 0.40 ± 0.09 
for the extract) are shown in Table 5.  The Table also shows that a 5%w/v mixture of the 
herb had pH of 5.7 ± 0.3, while that of the extract was 6.9 ± 0.3. The herb in water foamed 
slightly (that is: Foaming Index [FI] ≤ 100), but the extract did not foam at all (that is: FI = 0). 
Table 5 further shows that the herb in methanol/water (80/20: v/v) had an A1%1cm of 
325.8 ± 15.6, while that of the extract was 349.5 ± 14.1. The Table also shows the 
extractabilities of the herb in various solvents. The extractability results expressed as 
(%w/w) were as follows: acetone, 6.89 ± 0.89; water, 28.37 ± 1.77; ethanol, 11.72  ± 0.81; 
ethylacetate, 14.02  ± 1.89; hexane, 4.11 ± 0.47; and methanol, 15.11 ± 1.07. The extractability 
of the air-dried weed was highest in water and least in hexane. Among the organic solvents, 
extractability was lowest in hexane, and highest in methanol, followed by ethylacetate, 
ethanol and acetone.  
 
Parameter (Mean ± SD) Air-dried Herb Ethylacetate Extract 
Loss on drying (LOD: % w/w ) 10.29 ± 1.81 (n=12) 15.86 ± 0.72 (n=12) 
Total ash (TA: % w/w) 12.44 ± 2.95 (n=12) 0.40 ± 0.09 (n=11) 
pH of 5 % w/v in water 5.7 ± 0.3 (n=5) 6.9 ± 0.3 (n=5) 
Foaming Index (FI: as  ml-1) 
Slight foam. FI ≤ 100 
(n=5) 
No foam. FI = 0 
(n=5) 
A 1%1cm at ǌ227 nm  
(MeOH/ H2O: 80/20 v/v) 
325.8 ± 15.6 (n=5) 349.5  ± 14.1 (n=5) 
Extractability (% w/w) in: 
Solubility (ml/g) in: 
Extractive value (n=8-12) 
- 
- 
Solubility (n=2-6) 
Water  28.37 ± 1.77 >10³ 
Methanol 15.11 ± 1.07 25.0 ±  0.0 
Ethylacetate 14.02  ± 1.89 25.0 ±  5.0 
Ethanol 11.72  ± 0.81 25.0 ±  0.0 
Acetone 6.89 ± 0.89 15.0 ±  0.0 
Hexane 4.11 ± 0.47 55.0 ±  5.0 
The LOD results were validated by concurrent determination of the LOD of copper sulphate, which 
result (mean ± SD) was 36.12 ± 0.19 %. The results prove that the extract was quite hygroscopic. The low 
TA results for the extract but not the herb probably suggests a high presence of high bio-minerals. The 
high water extractability result agrees with the high TA of the herb, and the fact that hexane, the least 
polar solvent, produced the lowest extractability result. Among the organic solvents the solubility of the 
extract was least in hexane (55 ml/g), but higher in ethanol, ethylacetate and methanol (15-25 ml/g). 
The extract was practically insoluble in water (>10³ml/g). The colour of the solution obtained from the 
herb using different organic solvents was clear and greenish-brown in each case, but that obtained with 
water was yellowish brown, and slightly cloudy, with no tinge of green.  
Table 5. Various physicochemical parameters of herb and extract of Mitracarpus scaber. 
3.3 Results of thin layer chromatographic (TLC) studies on the herb and extracts of  
M. scaber  
Figure 1 is a normal phase TLC of the herb and extract developed with hexane-ethylacetate. 
The Figure indicates the following: The herb in acetone (A) or ethanol (C) yielded 5 identical 
www.intechopen.com
 
Modern Approaches To Quality Control 376 
principal spots, while the herb in water (B) yielded only 2 principal spots – Rf1 and Rf4. The 
herb in ethylacetate (D) or hexane (E) yielded 3 spots, while the herb (F) in methanol yielded 
4. The dry hexane extract (G) re-dissolved in hexane yielded 7 spots, while the ethylacetate 
extract (H) re-dissolved in ethylacetate yielded 10. Notably, Rf4 was present in all the 
chromatograms, while Rf2 and Rf3 were present only in the H chromatogram. On the other 
hand Rf1 was present only in the B, G and H chromatograms.  
 
A: M. scaber in Acetone
B: M. scaber in Water
C: M. scaber in Ethanol
D: M. scaber in Ethylacetate
E: M. scaber in Hexane
F: M. scaber in Methanol
G: Hexane extract in Hexane
H: Ethylacetate extract in Ethylacetate
G and H were dry extracts re-dissolved in 
hexane and ethylacetate respectively
Rf as detected  with light at λ366nm
Rf1: 0.07
Rf2: 0.13
Rf3: 0.22
Rf4: 0.41
Rf5: 0.49
Rf6: 0.71
Rf7: 0.73
Rf8: 0.79
Rf9: 0.84
Rf10: 0.86
Rf1
Rf2
Rf3
Rf4
Rf5
Rf6
Rf7
Rf8
Rf10
Rf9
Origin
Solvent front
A B C D E F G H
  
The above diagram is of a normal phase TLC (K5 Silica, using hexane: ethylacetate at 60:40 v/v as 
mobile phase) of samples of samples of herb and extracts in various solvents as follows. Types of 
samples/ solvents: A: Herb in Acetone, B: Herb in Water, C: Herb in Ethanol, D: Herb in Ethylacetate, E: 
Herb in Hexane, F: Herb in Methanol, G: Hexane extract in Hexane, H: Ethylacetate extract in 
Ethylacetate. The samples in G and H were dry extracts re-dissolved in hexane and ethylacetate 
respectively. Rf as detected at ǌ366nm: Rf1: 0.07, Rf2: 0.13, Rf3: 0.22, Rf4: 0.41, Rf5: 0.49, Rf6: 0.71, Rf7: 
0.73, Rf8: 0.79, Rf9: 0.84, Rf10: 0.86. Descriptions/interpretations: The herb in acetone (A) or ethanol (C) 
yielded 5 identical principal spots, while the herb in water (B) yielded only 2 principal spots – Rf1 and 
Rf4. The herb in ethylacetate (D) or hexane (E) yielded 3 spots, while the herb (F) in methanol yielded 4. 
The dry hexane extract (G) re-dissolved in hexane yielded 7 spots, while the ethylacetate extract (H) re-
dissolved in ethylacetate yielded 10. Notably, Rf4 was present in all the chromatograms, while Rf2 and 
Rf3 were present only in the H chromatogram. On the other hand Rf1 was present only in the B, G and 
H chromatograms.  
Fig. 1. Diagrammatized normal phase TLC of M. scaber extracts showing up to ten principal 
spots. 
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Table 6. Effect of storage on herb and ethylacetate extract of M. scaber as evaluated by 
appearance,  extractability, solubility and loss on drying. 
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3.4 Effect of storage on herb and ethylacetate extract of M. scaber as evaluated by 
appearance, extractability, solubility and loss on drying 
Table 6 shows that the general appearance of the herb as wrinkled, brownish green/ grey 
leaves and twigs remained essentially unchanged up to the 39th month of storage. However, 
the extractability of the herb in water fell slightly but significantly as from after the 3rd 
month of storage. Table 6 also shows that neither the solubility profile nor the appearance of 
the extract and the solutions made from them in different solvents changed with storage. 
The same Table 6 shows that storage of the herb and the extract in capped glass bottles at 
room temperature and humidity (RTH) for up to 39 months produced no consistent or 
statistically significant changes in moisture content.  
3.5 Effect of storage on light absorption and TLC features of the herb and extract  
Table 7 presents the effect of storage on light absorption and TLC features of the herb and 
extract. It shows the following: that the difference in absorbance between 0th month and the 
21st/ 39th months was insignificant for the herb (P > 0.05). By contrast, the corresponding 
difference for the extract was significant (P < 0.05). Table 7 also shows that the number of 
TLC spots observed for the herb and extract at every stage of storage was unchanged up to 
the 39th month.  
 
Months of 
storage in 
capped 
glass bottles 
at RTH 
Herb Extract 
Abs. at 
λ227 nm 
Types of solvent/ number of TLC  
spots Abs. at 
λ227 nm 
TLC spots 
A B C D E F 
G H 
0 
2.172 ± 
0.104 (5) 
5 2 5 3 3 4 
2.330 ±  
0.094 (5) 
7 10 
3 
2.221 ±  
0.114 (6) 
5 2 5 3 3 4 
2.174 ± 
0.107 (5) 
7 10 
9 
2.144 ±  
0.098 (5) 
5 2 5 3 3 4 
2.104 ± 
0.070 (5) 
7 10 
21 
2.322 ±  
0.117
a
(5) 
5 2 5 3 3 4 
2.039 ±  
0.104
b
(5) 
7 10 
39 
2.233 ±  
0.114
a
 
(5) 
5 2 5 3 3 4 
2.084±  
0.111
b
(6) 
7 10 
For the herb, the difference in absorbance between 0th month and the 21st/ 39th months, denoted by 
(a), was insignificant (P > 0.05). By contrast, for the extract, the difference in absorbance between the 0th 
or 3rd month and the 21st or 39th month, denoted by (b), was significant (P < 0.05). Notably, the 
number of TLC spots observed for both the herb and extract remained unchanged up to the 39th month.  
Table 7. Effect of storage on light absorption and TLC characteristics of herb and extract of 
M. scaber. 
3.6 Effect of storage on pH and foaming indices of herb and ethylacetate extract of  
M. scaber 
Table 8 shows that the pH of a 5 %w/v mixture of the herb or extract in water did not 
change significantly with storage for up to 39 months. However, although the 5 %w/v 
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mixture of the fresh plant material in water did foam slightly; this property diminished 
rapidly, and was totally lost after the 3rd month of storage. By contrast, the ethylacetate 
extract never foamed at any stage of storage.  
 
Months of storage in 
capped glass  bottles 
at RTH 
pH  of mixture (5% w/v) Foaming index 
Herb in 
water 
Ethyl acetate 
extract in 
water 
Herb in 
water 
Ethylacetate 
extract in water 
Within 1st day of 
harvest or 
preparation 
5.7 ± 0.3 (5) 6.9 ± 0.3 (5) 
Foam: Slight 
≤  100 (5) Foam: Nil (5) 
0 5.9 ± 0.2 (6) 6.1 ± 0.3 (5) 
Foam: Slight 
<  100 (5) 
Foam: Nil (6) 
3 5.6 ± 0.2 (5) 6.2 ± 0.4 (6) 
Foam: Slight 
<  100 (5) 
Foam: Nil (5) 
9 5.4 ± 0.2 (5) 6.1 ± 0.3 (5) 
Foam: Nil 
(6) 
Foam: Nil (5) 
21 5.9 ± 0.3 (7) 6.7 ± 0.3 (5) 
Foam: Nil 
(5) 
Foam: Nil (5) 
39 5.9 ± 0.3 (5) 6.5 ± 0.3 (5) 
Foam: Nil 
(5) 
Foam: Nil (5) 
Both (a) and (b) indicate that the pH of the 5 %w/v aqueous mixtures at every stage fell within the 
mean values of 5.8 ± 0.2a and 6.4 ± 0.4b - they indicate that any deviations from these mean values were 
insignificant (P > 0.05). The freshly harvested samples foamed measurably, but the ability was totally 
lost after the 3rd month of dry storage. In all cases however, the dry ethylacetate extract was virtually 
insoluble in water, and did not foam at all. 
Table 8. Effect of storage on pH and foaming indices of the fresh plant material, the dry herb 
and the ethylacetate extract of M. scaber. 
4. Discussions 
The aim of this study was to apply official methods of WHO (1998) and BP (2004) to study 
the key quality attributes of the air-dried weed and the ethylacetate extract of Mitracarpus 
scaber, for the purpose of quality control, GMP production and registration of Niprifan by 
NAFDAC. WHO had defined “Herbal Substance” as “Material derived from the plant(s) by 
extraction, mechanical manipulation, or some other process” (WHO, 2005). Thus, either the 
ethylacetate extract, or even the comminuted, air-dried vegetable matter, may rightly be 
termed the “Herbal Substance” of Niprifan. Since the advent of the Alma-ata Declaration in 
1978, many developing countries opted to adopt the WHO model in developing their 
National Traditional Medicine, especially phytotherapy (Ameh et al., 2010b). NIPRD’s 
adherence to the WHO model had resulted in the sickle cell drug – Niprisan, developed 
from Yoruba Traditional Medicine (Wambebe et al., 2001). It is generally held that in most 
countries, especially in Africa, the populations depend greatly on herbal remedies, up to 90 
% in some instances like Ethiopia (BBC, 2006). Such high dependence calls for a system or 
mechanism for harnessing and optimizing all or most of such plant resources. That means 
that every effort must be made to obtain maximum benefits from them. One way to do this 
is to standardize the raw materials used in producing the remedies, by studies such as this 
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one. Such studies will at least help to minimize waste, and even lead ultimately to 
conservation of endangered plants. Indeed, efforts at conservation are more likely to 
succeed when the value of what is to be conserved is proven.  
Our immediate interest however, is in the need to entrench the use of these resources by 
taking appropriate actions, which, in this case is - an application to NAFDAC to consider the 
registration of Niprifan, based on folkloric use evidence, pertinent literature, and the 
experimental data provided in this study. These three lines of evidence can be summarized 
as follows. At the peak of British colonialism in Africa considerable effort was made to 
harness the continent’s wealth in herbal traditions. Thus at as far back as the 1930s a team of 
British scientists had combed the entire West Africa to research traditional herbal remedies. 
Thus, for Mitracarpus scaber, Hutchinson and Dalziel (1948) reported a number of findings 
that have subsequently been confirmed by work in NIPRD and elsewhere (Benjamin et al., 
1986; Irobi and Daramola, 1994; Cimanga et al., 2004; Abere et al., 2007a, 2007b). These 
include the following:  that M. scaber was widely distributed and used topically in all of 
West Africa for various skin infections; and orally for various internal conditions. Among 
the traditional indications mentioned, and which have since been confirmed by NIPRD’s 
Ibrahim Muaazzam (ethnobotanist and consultant on TM) are: leprosy, lice, ringworm, 
eczema and craw-craw. Currently, the plant is used orally for sore throat, for which purpose 
it is wholly macerated in water.  
Among the vernacular names of M. scaber are: Hausa (goga masu); Fulani (gadudal); Yoruba 
(irawo-ile); and Ibo (obu obwa). Professor Ogundiani (2005) in his inaugural address at the 
University in Ile-Ife commented on Niprifan,  
stressing the antimicrobial potency of M. scaber. Ogundiani, as stated in the lecture, had 
been unaware of the NIPRD’s work on Niprifan, until shortly before the inaugural, since 
that work, led by Professors Wambebe, Okogun and Nasipuri, had been unpublished. 
Therefore, in this paper we elect to present not only these historical antecedents, but also 
to furnish the results of our evaluation of the key quality variables of the herb and extract 
of M. scaber, with a view to advancing the registration of Niprifan (for skin infections) by 
NAFDAC. The results here presented probably suffice for quality control and GMP 
production, particularly if more emphasis is placed on technical requirements than on 
bureaucracy. It must be remarked at this juncture that NAFDAC only belatedly 
recognized the sickle cell drug, Niprisan, after the US-FDA and EMEA had granted it 
orphan status (Pandey, 2003). One may wonder - What a paradox! Why should the US 
and Europe that need herbal drugs far less than Nigeria be keener in their regulation?  
Therefore, from the foregoing, it seems that the key to this Nigerian enigma lies not in the 
technical but in the non-technical differences between NAFDAC and EMEA as depicted in 
Tables 1-3. The said differences which hinge on NAFDAC’s extra requirements (Table 3) 
suggest that NAFDAC needs to re-strategize for efficient discharge of its Mandate. For 
example, despite the widespread use of herbal medicines in Nigeria and the Federal 
Policy on TM (2007), NAFDAC is not known to have “fully registered” a single herbal 
medicine since its creation in 1992/3, whereas it should. This is the puzzle this article had 
hoped to address. 
5. References  
Abere , T. A.; Onyekweli, A. O. & Ukoh, G. C. (2007a). In vitro Antimicrobial Activity of the 
Extract of Mitracarpus scaber Leaves Formulated as Syrup. Tropical Journal of 
Pharmaceutical Research Vol. 6, No. 1, pp. 679-682.  
www.intechopen.com
 
Herbal Drug Regulation Illustrated with Niprifan® Antifungal Phytomedicine 381 
Abere, T. A.; Onwukaeme, D. N. & Eboka, C. J. (2007b). Pharmacognostic evaluation of the 
leaves of Mitracarpus scaber Zucc (Rubiaceae). Tropical Journal of Pharmaceutical 
Research Vol. 6, No. 4, pp. 849-853.  
Ameh, S. J.; Obodozie, O. O.; Inyang, U. S.; Abubakar, M. S. & Garba, M. (2010a). Current 
phytotherapy – an inter-regional perspective on policy, research and development 
of herbal medicine. Journal of Medicinal Plants Research Vol. 4(15), pp 1508-1516, 4 
August, 2010. 
Ameh, S. J.; Obodozie, O. O.; Inyang, U. S.; Abubakar, M. S. & Garba, M. (2010b). Current 
phytotherapy - A perspective on the science and regulation of herbal medicine. 
Journal of Medicinal Plants Research; Vol. 4(2): 072-081. 
Ameh, S. J.; Tarfa, F. D.; Abdulkareem, T. M.; Ibe, M. C.; Onanuga, C. & Obodozie, O. O. 
(2010c). Physicochemical Analysis of the Aqueous Extracts of Six Nigerian 
Medicinal Plants. Tropical Journal of Pharmaceutical Research, 9 (2): 119-125. 
Ameh, S. J.; Obodozie, O. O.; Inyang, U. S.; Abubakar, M. S. & Garba, M. (2010d). Quality 
Control Tests on Andrographis paniculata Nees (Family: Acanthaceae) – an Indian 
‘Wonder’ Plant Grown in Nigeria. Tropical Journal of Pharmaceutical Research, Vol. 9, 
No 4, pp. 387-394 
Ann Godsell Regulatory (2008). Pharmaceutical Good Manufacturing Practice for Herbal 
Drug Substances 2008 [cited 2010 April 8]. Available online at:  
 http://www.pharmaceutical-int.com/article/category/treatment-herbal-
medicines 
BBC News (2006). Can herbal medicine combat Aids? Wednesday, 15 March, 13:10 GMT. 
http://newsvote.bbc.co.uk/mpapps/pagetools/print/news.bbc.co.uk/2/hi/Afric
a/4793106.stm . 
Benjamin, T. V.; Anucha, T. C. & Hugbo, P. G. (1986). An approach to the study of medicinal 
plants with antimicrobial activity with reference to Mitracarpus scaber. In: Sofowora, 
A. (Ed.) The State of medicinal Plants Research in Nigeria, pp. 243-245, Ibadan 
University Press, ISBN 978-30285-0-2, Ibadan, Nigeria. 
Bisignano, G.; Sanogo, R.; Marino, A.;  Angelo, V.; Germano, M.; De Pasquale, R. & Pizza, C. 
(2000). Antimicrobial activity of Mitracarpus scaber extract and isolated 
constituents. Letters in Applied Microbiology, Vol. 30, pp. 105-108. doi:10.1046/j.1472-
765x.2000.00692.x. 
Cimanga, R. K.; Kambu, K.; Tona, L.; Bruyne, T.; Sandra, A.; Totte, J.; Pieters, L. & Vlietinck, 
A. J. (2004). Antibacterial and antifungal activities of some extracts and fractions of 
Mitracarpus scaber Zucc. (Rubiaceae). Journal of Natural Remedies, Vol. 4, No. 1, pp. 
17-25  
De Smet, P. N. (2005). Herbal medicine in Europe – relaxing regulatory standards. New 
England Journal of Medicine, Vol. 352, No. 12, pp. 1176-78. 
DSHEA (1994). Dietary Supplements Health Education Act of 1994 [cited 2010 April 8]. 
Available at: http://fda/Food/DietarySupplements/ucm109764.htm   
Gbaguidi, F.; Accrombessi, G.; Moudachirou, M. & Quetin-Leclercq, J. (2005). HPLC 
quantification of two isomeric triterpenic acids isolated from Mitracarpus scaber 
and antimicrobial activity on Dermatophilus congolensis. Journal of Pharmaceutical 
& Biomedical Analysis, Vol. 39, No. 5, pp. 990-995.  
www.intechopen.com
 
Modern Approaches To Quality Control 382 
Germanò, M. P.; Sanogo, R; Costa, C; Fulco, R; D’Angelo, V.; Viscomi, E. G. & de Pasquale, 
R. (1999). Hepatoprotective Properties in the Rat of Mitracarpus scaber (Rubiaceae). 
Journal of Pharmacy & Pharmacology, June 1999. Vol. 51, No. 6, pp. 729-734. 
Goldman, P. (2001). Herbal medicines today and the roots of modern pharmacology. Annual 
Internal Medicine, Vol. 135, No. 8, Pt 1, pp. 594–600. 
Gross, A. & Minot, J. (2007). Chinese Manufacturing: Scandals and Opportunities. Published 
in MX, November/ December, Pacific Bridge Medicals.  
 http://www.pacificbridgemedicals.com/  
Houghton, P. J.; Ibewuike, J. C.; Mortimer, F.; Okeke, I. N. & Ogundaini, A. O. (2002). 
Antibacterial quinones from Mitracarpus scaber. Journal of Pharmacy & 
Pharmacology, 52 (Suppl.) 261. 
 www.kcl.ac.uk/content/1/c6/01/66/69/PUB82008.pdf 
Hutchinson, J. & Dalziel, J. M. (1948). The flora of West Tropical Africa. Crown Agents for the 
Colonies. 4 Millbank, Westminster, London, SW1., London. Vol 11. 1948. p. 222. 
Irobi, O. N. & Daramola, S. O. (1994). Bactericidal properties of crude extracts of 
Mitracarpus villosus. Journal of Ethnopharmacology, Vol. 42, No. 1, pp. 39-43.  
NAFDAC’s website (2010). Website of the National Agency for Food and Drug 
Administration and Control. www.nafdacnigeria.org/  
Ogundaini, A. O. (2005). From Greens into Medicine: Taking a Lead From Nature.  
Inaugural Lecture Series 176. Ile-Ife. Tuesday 26, April. Obafemi Awolowo 
University Press Limited 
Okunade, A. L.; Clark, A. M.; Hufford, C. D. & Oguntimein, B. O. (1999). Azaanthraquinone: 
an antimicrobial alkaloid from Mitracarpus scaber [letter] Planta Medica,Vol. 65, 
No. 5, pp. 447-8.  
Pandey, R. C. (2003). Xechem's Sickle Cell Drug, NIPRISAN – HEMOXIN Granted Orphan 
Drug Status by the FDA NEW BRUNSWICK, N.J.-- (BUSINESS WIRE)--Sept. 2, 
2003--Xechem International, Inc. (OTC BB: XKEM). 
Pelletier, K. R. (2009). Guide to Herbal Medicine (cited 2009 June 2). Available from: 
http://www.ca.encarta.msn.com/sidebar_701509401/Guide_to_Herbal_Medicine.
html   
Wambebe, C;  Khamofu, H.; Momoh, J.; Ekpeyong, M.; Audu, B.; Njoku, B. S.; Nasipuri, N. 
R.; Kunle,  O. O. et al. (2001). Double-blind, placebo-controlled, randomized cross-
over clinical trial of NIPRISAN in patients with sickle cell disorder. Phytomedicine, 
8(4):252-61. 
WHO (1998). Quality control methods for medicinal plant materials. World Health 
Organization, WHO, Geneva, pp. 1-115. 
WHO (2000). General guidelines for methodologies on research and evaluation of 
traditional medicine (Document WHO/EDM/ TRM/2000.1). World Health 
Organization, WHO, Geneva. pp. 1-184. 
WHO (2005) APPENDIX 2 Glossary of key terms. In: Information needed to support Clinical 
Trials of herbal products. TDR/GEN/Guidance/05.1Operational Guidance: Special 
Programme for Research and Training in Tropical Diseases, WHO, Geneva, pp. 1-
16. 
www.intechopen.com
Modern Approaches To Quality Control
Edited by Dr. Ahmed Badr Eldin
ISBN 978-953-307-971-4
Hard cover, 538 pages
Publisher InTech
Published online 09, November, 2011
Published in print edition November, 2011
InTech Europe
University Campus STeP Ri 
Slavka Krautzeka 83/A 
51000 Rijeka, Croatia 
Phone: +385 (51) 770 447 
Fax: +385 (51) 686 166
www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai 
No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 
Fax: +86-21-62489821
Rapid advance have been made in the last decade in the quality control procedures and techniques, most of
the existing books try to cover specific techniques with all of their details. The aim of this book is to
demonstrate quality control processes in a variety of areas, ranging from pharmaceutical and medical fields to
construction engineering and data quality. A wide range of techniques and procedures have been covered.
How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
Sunday J. Ameh, Obiageri O. Obodozie, Mujitaba S. Abubakar, Magaji Garba and Karnius S. Gamaniel (2011).
Herbal Drug Regulation Illustrated with Niprifan® Antifungal Phytomedicine, Modern Approaches To Quality
Control, Dr. Ahmed Badr Eldin (Ed.), ISBN: 978-953-307-971-4, InTech, Available from:
http://www.intechopen.com/books/modern-approaches-to-quality-control/herbal-drug-regulation-illustrated-
with-niprifan-antifungal-phytomedicine
© 2011 The Author(s). Licensee IntechOpen. This is an open access article
distributed under the terms of the Creative Commons Attribution 3.0
License, which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
